Current data does not establish a definitive causal link between GLP-1 medications and bone loss , but several studies have examined potential associations
Retatrutide activates three hormone receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors
This may be helpful information if you are having side effects and want to switch from one weight-loss approved GLP-1 to another
[11] [12] Those who believe they may benefit from emerging treatments like retatrutide in the future should discuss this with their GP or a specialist, who can advise on clinical trial eligibility or monitor developments in licensing
Everything in life seems to have both pros and cons, and GLP-1s are no different
Team-based care, including registered dietitian nutritionists (RDNs), exercise physiologists, and health coaches, can be very helpful, but these are not always available depending on health system circumstances and payer policies